---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-028590"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2026-08-20T11:04:58+00:00"
generated_at: "2026-08-20T11:10:07.529610+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# UroGen secures exclusive option to license IntraGel's TumoCure for head and neck cancer; invests up to $7M

## Summary
- On Aug 18, 2026, UroGen U.S. entered an Option and Research License Agreement with IntraGel Therapeutics for TumoCure (head and neck cancer).
- UroGen obtained exclusive option for worldwide license to develop/commercialize TumoCure using IntraGel's SRGel biodegradable hydrogel platform.
- Also obtained options for additional SRGel-based products with UroGen-designated compounds, plus non-exclusive research license.
- UroGen agreed to invest up to $7,000,000 in IntraGel equity via Securities Purchase Agreement on same date.

## SEC filing metadata
- accession: 0001437749-26-028590
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2026-08-20T11:04:58+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000143774926028590/0001437749-26-028590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000143774926028590/urgn20260819_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-028590
- JSON: https://secwatch.observer/filing/0001437749-26-028590.json
- Plain text: https://secwatch.observer/filing/0001437749-26-028590.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.